CD51 Targeting for T-Cell Malignancy Diagnosis and Immune Escape
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for T-cell malignancies, such as Sézary syndrome and T-cell lymphomas, are limited by the lack of specific markers for diagnosis and effective therapeutic targets, leading to difficult initial diagnosis and rare long-term responses, with existing therapies like anti-CCR4 monoclonal antibodies causing autoimmune reactions.
Innovation Solution
The use of CD51 as a diagnostic and therapeutic target, employing CD51 inhibitors and antibodies to block CD51-induced TGF-beta production, which contributes to immune escape of tumor cells, and agents that induce cell death of CD51-expressing cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD51 inhibitors or antibodies are used to block CD51-induced TGF-beta production, then immune escape of tumor cells is reduced, but the complexity of the treatment mechanism increases
Solution Approach 1:
The patent extracts and targets the specific CD51-TGF-beta immune escape pathway from the complex T-cell malignancy system. By focusing on this particular mechanism, the treatment achieves diagnostic accuracy and therapeutic efficacy without needing to address all possible pathways, thus managing complexity while improving reliability
Solution Approach 2:
The patent changes the parameter of marker specificity by identifying CD51 as a diagnostic and therapeutic target. This parameter change enables both accurate diagnosis and effective treatment through a single target, resolving the contradiction between diagnostic accuracy and treatment complexity
2Reliability
If existing therapies like anti-CCR4 monoclonal antibodies are used, then progression-free survival is improved, but autoimmune adverse reactions occur
Solution Approach 1:
The patent applies local quality by targeting CD51 specifically on T-cell malignancy cells rather than broadly affecting all T cells. This localized targeting achieves therapeutic efficacy while minimizing the autoimmune adverse reactions that occur with broader targets like CCR4
Solution Approach 2:
The patent converts the harmful TGF-beta-mediated immune escape mechanism into a therapeutic target. By blocking the harmful TGF-beta production induced by CD51, the treatment transforms the cancer's immune evasion strategy into a vulnerability that can be exploited for therapy
3Measurement precision
If CD51 is used as a diagnostic target, then diagnostic accuracy is enhanced, but the difficulty of detecting and measuring increases
Solution Approach 1:
The patent makes CD51 a universal target that serves multiple functions: it is both a diagnostic marker and a therapeutic target. This multi-functionality allows the same marker to be used for both accurate detection and effective treatment, enhancing diagnostic accuracy while managing detection difficulty through standardized methodologies
Data Source
AI summary
T-cell malignancies are a broad, heterogenous group of diseases and include T-cell lymphomas and T-cell leukemias. T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sézary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors showed that both circulating malignant and non-malignant T cells express CD51 in patients with Sézary syndrome. CD51 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas.